Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.

Background: The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.

Methods: This retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.

Results: Most frequent treatment patterns among Stage I/II patients ( = 84) were surgery only (48.

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.

Introduction: To date, lung cancer is one of the most lethal diagnoses worldwide. A variety of lung cancer treatments and modalities are available, which are generally presented during the patient and doctor consultation. The implementation of decision tools to facilitate patient's decision-making and the management of their healthcare process during medical consultation is fundamental.

Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy.

Sarcoidosis and sarcoid-like reactions have been associated with many solid tumors including malignant melanoma. There are reports of melanoma patients who develop sarcoidosis without having received any antineoplastic treatment, but there are also melanoma patients who have received immunotherapy or targeted therapy and, therefore, develop drug-associated sarcoidosis. Herein, we describe 2 cases of thoracic sarcoidosis which occurred in asymptomatic patients with known malignant melanoma.

Epidemiology of active tuberculosis in lung cancer patients: a systematic review.

Objectives: The aim of this review article is to evaluate the available literature concerning the prevalence of active tuberculosis in lung cancer patients.

Data Source: MEDLINE, PubMed, EMBASE and Medscape databases were searched for studies with quantitative data on the interaction between tuberculosis (TB) and lung cancer, published since 1952. We used the Medical Subject Headings' term 'tuberculosis' and the text-word terms 'TB' and 'Mycobacterium infection', and also, the Medical Subject Headings' terms 'neoplasm' and 'lung neoplasm', or the text-word term 'lung cancer'.

Multimodal treatment strategies for elderly patients with head and neck cancer.

The population in developed countries is growing older and the number of elderly people annually diagnosed with head and neck cancers is expected to rapidly increase within the following decades, since these types of tumors are age-dependent. The vast majority of older head and neck cancer patients present with locally advanced disease and multimodality treatment, including surgery, radiation and/or chemotherapy, is considered the best therapeutic option for these patients. However, several factors, including comorbidities, disabilities, frailty, and impaired functional status are considered to be more relevant criteria than chronological age per se for treatment planning.

Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.

Pancreatic adenocarcinoma is one of the most aggressive malignancies and the fourth leading cause of cancer-related mortality in the United States. The majority of patients are diagnosed at advanced stage with inoperable locally advanced tumors or metastatic disease, and palliative chemotherapy remains the best therapeutic option for these patients. Despite intensive clinical and pre-clinical research over the last few years, the combination of the anti-metabolite drug gemcitabine with the targeted agent erlotinib, is considered standard of care in the treatment of these patients, with only minimal or modest efficacy.

Pancreatic cancer: updates on translational research and future applications.

Pancreatic cancer is one of the most lethal malignancies with a mortality rate almost equal to its incidence. It is ranked as the fourth leading cause of cancer-related deaths in the United States, and despite intensive basic and clinical research over the last few years, the survival benefit for the majority of patients with pancreatic cancer is still disappointing. Due to the absence of specific symptoms and the lack of early detection tests, pancreatic cancer is usually diagnosed at an advanced inoperrable stage and palliative chemotherapy with the purine analogue gemcitabine in combination with the targeted agent erlotinib, remains the mainstay method in the management of these patients.

The Biological Role of PI3K Pathway in Lung Cancer.

Lung cancer is the primary cause of cancer-related mortality worldwide and although improvements in treatment have been achieved over the last few years, long-term survival rates for lung cancer patients remain poor. Therefore, there is an imperative need for molecularly targeted agents that will achieve long-term disease control. Numerous downstream molecular pathways, such as EGF/RAS/RAF/MEK/ERK and PI3K/AKT/mTOR are identified as having a key role in the pathogenesis of various forms of human cancer, including lung cancer.

Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin.

The authors report on a 66-year-old hemodialysis patient who had diffuse alopecia while on anticoagulation treatment to prevent extracorporeal blood clotting with a low- molecular-weight heparin (LMWH), tinzaparin. The alopecia reversed completely when tinzaparin was substituted by another LMWH, enoxaparin. The biopsy findings, the possible mechanisms of heparin's action in the hair roots, and the restoration of the patient's hairs after the discontinuation of tinzaparin are discussed.